At Gain Therapeutics, we are uniquely positioned to capitalize on the AlphaFold project and
extend the scope of our existing technology.
Just last month, AlphaFold launched their Protein Structure Database, containing high-quality predicted structures of every protein in the human body.
For years, the neuroscience industry has been plagued by a high failure rate of drugs in the clinical stages.
“We were thrilled to complete our IPO in March on the Nasdaq Global Market Exchange,” stated Sal Calabrese, Chief Financial Officer of Gain.
Gain Therapeutics, Inc. is redefining drug discovery with its SEE-Tx™ target identification platform. By identifying and optimizing allosteric binding sites that have never before been targeted
Corporate Presentation